Longer Anti-Platelet Therapy Reduces Thrombosis Risks With Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.
You may also be interested in...
Starts & Stops: Abbott And Boston Scientific Lead Big List Of Trial Announcements
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions, and suspensions each month. This month's edition, covering the period between mid-June and mid-July, represents a wide variety of devices and companies, including many of the biggest medtech players.
Top Device Research Payments: PARTNER II, Cardio, Neuro, Dx Device Trials Highest In 2014
The transcatheter aortic valve PARTNER II study, several stent trials, and studies looking at diagnostic tools and neurological devices dominated the top ten trials by total payment to clinical investigators in 2014, according to an analysis of CMS' Open Payments database.
Top Research Payments: PARTNER II, Cardio, Neuro, Dx Device Trials Highest In 2014
The transcatheter aortic valve PARTNER II study, several stent trials, and studies looking at diagnostic tools and neurological devices dominated the top ten trials by total payment to clinical investigators in 2014, according to a "Gray Sheet" analysis of CMS' Open Payments database.